Jaiwik Biotech Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 1.00 M
- Company Age 4 Year, 3 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 11.40 Cr
- Revenue Growth 136716.40%
- Profit Growth -858.51%
- Ebitda 2281.50%
- Net Worth -647.07%
- Total Assets 61.84%
About Jaiwik Biotech
Jaiwik Biotech Private Limited (JBPL) is a Private Limited Indian Non-Government Company incorporated in India on 10 November 2020 (Four years and three months 14 days old ). Its registered office is in Jaipur, Rajasthan, India.
The Company is engaged in the Chemicals And Materials Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M.
The company currently has active open charges totaling ₹11.40 Cr.
Nand Bhawsar and Amit Agarwal serve as directors at the Company.
Company Details
- Location
Jaipur, Rajasthan, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24290RJ2020PTC072051
- Company No.
072051
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
10 Nov 2020
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Jaipur
Industry
Who are the key members and board of directors at Jaiwik Biotech?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Nand Bhawsar  | Director | 10-Nov-2020 | Current |
| Amit Agarwal | Director | 10-Nov-2020 | Current |
Financial Performance of Jaiwik Biotech.
Jaiwik Biotech Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 136716.4% increase. The company also saw a substantial fall in profitability, with a 858.51% decrease in profit. The company's net worth observed a substantial decline by a decrease of 647.07%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Jaiwik Biotech?
Unlock access to Jaiwik Biotech's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
₹114.03 M
₹0
Charges Breakdown by Lending Institutions
- Others : 11.40 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 30 Nov 2023 | Others | ₹4.60 Cr | Open |
| 19 Mar 2022 | Others | ₹9.00 M | Open |
| 18 Feb 2021 | Others | ₹3.90 Cr | Open |
| 18 Feb 2021 | Others | ₹2.00 Cr | Open |
How Many Employees Work at Jaiwik Biotech?
Jaiwik Biotech has a workforce of 28 employees as of Jun 19, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Jaiwik Biotech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Jaiwik Biotech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.